ENTA
ENANTA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$12.20
−2.56%Sep 16, 2026, 08:45 UTC
Entain launched a consultation to cut around 400 customer care jobs, about a fifth of its 2,000-strong global customer care workforce across 11 countries including the UK, citing increased UK gambling taxes.
Source:Aug 10, 2026, 22:11 UTC
Enanta Pharmaceuticals reported a Q3 2026 loss of $0.67 per share, missing the Zacks Consensus Estimate of a loss of $0.37, and compared to a loss of $0.85 per share a year ago.
Source:Jun 23, 2026, 09:10 UTC
AbbVie received European Commission approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus in the European Union.
Source: